TY - JOUR T1 -人类受试者的最小雾化干扰素剂量:JF -欧洲呼吸杂志JO - Eur Respir J SP - 42 LP - 46 VL - 9 IS - 1 AU - Giosue, S AU - Casarini, M AU - Ameglio, F AU - Alemanno, L AU - Saltini, C AU - Bisetti，A Y1 - 1996/01/01 UR - //www.qdcxjkg.com/content/9/1/42.abstract N2 -干扰素-alpha (IFN-alpha)是一种白细胞来源的细胞因子，对免疫系统细胞具有多效性作用，包括促进病毒和微生物的杀伤能力。本研究旨在评估雾化的淋巴母细胞ifn - α的生物活性剂量，在正常受试者和慢性支气管炎患者中，使用血清2’-5’寡聚腺苷酸合成酶(OAS)作为ifn - α活性的标记物。纳入3组受试者:2个健康组和1个慢性支气管炎患者。A组(对照组，n = 5)的研究是为了确定能够诱导生物学效应而无副作用的最小干扰素- α剂量。IFN-alpha在一项剂量递增试验中被给予，包括0、0.3 × 10(6)、1.0 × 10(6)和3.0 × 10(6) IU。第1天(5天管理)。仅给予3.0 × 10(6) IU。第1天ifn - α诱导了显著的生物活性，增加了血清OAS水平。B组(对照组，n = 5)和C组(慢性支气管炎组，n = 5)给予3.0 × 10(6) IU。day-1 (10 day administration) in order to study serum, bronchoalveolar lavage fluid (BALF) and BALF cell modifications, after treatment. OAS serum levels and nitroblue tetrazolium (NBT) reduction tests, the latter used as a measure of phagocyte cell activity, increased both in normal subjects and in patients with chronic bronchitis. No significant change of serum IFN-alpha levels was found. It is concluded that aerosolized IFN-alpha administration to the lung is well-tolerated at biologically active doses. The activity can be monitored by quantifying OAS serum levels through a simple blood test. ER -